Skip to main content
Top
Published in: PharmacoEconomics 8/2005

01-08-2005 | Original Research Article

Societal discounting of health effects in cost-effectiveness analyses

The influence of life expectancy

Authors: Dr Suzanne Polinder, Willem Jan Meerding, Job van Exel, Werner Brouwer

Published in: PharmacoEconomics | Issue 8/2005

Login to get access

Abstract

Background: Increasing life expectancy and decreasing marginal valuation of additional QALYs over time may serve as a basis for discounting future health effects from a societal perspective. Therefore, we tested the hypothesis that societal time preference for health is related to perceived future life expectancy.
Methods: A sample of 223 people from the general population prioritised healthcare programmes with differential timing of health benefits and costs from a societal perspective. Furthermore, we asked respondents to estimate future life expectancy.
Results: The relationship between future life expectancy and time preference for health is ambiguous. We observed that people who expected a higher future life expectancy elicited higher discount rates for health effects than those with lower life expectancy growth expectations for all four time periods (5, 10, 20 and 40 years into the future), but the differences were never significant. On average, providing explicit information on growth in life expectancy did significantly alter discount rates in the expected direction but, on an individual level, the results were rather inconsistent. We observed a significantly stronger time preference (i.e. higher discount rates) for health effects than for costs. As commonly observed, discount rates for health and money decreased with time delay following a hyperbolic function.
Conclusion: Our data indicate that it is troublesome to elicit societal discount rates empirically, especially rates that are in line with the theoretical arguments on societal discounting. The influence of life expectancy remains ambiguous, but there seems to be at least some positive relationship between growth in life expectancy and discount rates that deserves additional attention.
Appendix
Available only for authorised users
Footnotes
1
Discounting is calculated as 1/(1+r)n, where r is the discount rate and n is the number of years, in this case 1/1+0.51.
 
Literature
1.
go back to reference Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
2.
go back to reference Drummond MF, O’Brien B, Stoddard GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997 Drummond MF, O’Brien B, Stoddard GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
3.
go back to reference Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med 1977; 96: 716–71CrossRef Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med 1977; 96: 716–71CrossRef
4.
go back to reference Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci 1983; 29: 300–6CrossRef Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Manage Sci 1983; 29: 300–6CrossRef
6.
go back to reference Van Hout BA. Discounting costs and effects differently: a reconsideration. Health Econ 1998; 7: 581–94PubMedCrossRef Van Hout BA. Discounting costs and effects differently: a reconsideration. Health Econ 1998; 7: 581–94PubMedCrossRef
7.
go back to reference Smith D, Gravelle H. The practice of discounting economic evaluation of health care intervention. Int J Technol Assess Health Care 2001; 17 (2): 236–43PubMedCrossRef Smith D, Gravelle H. The practice of discounting economic evaluation of health care intervention. Int J Technol Assess Health Care 2001; 17 (2): 236–43PubMedCrossRef
8.
go back to reference Gravelle H, Smith D. Discounting for health effects in costbenefit and cost-effectiveness analysis. Health Econ 2001; 10: 587–99PubMedCrossRef Gravelle H, Smith D. Discounting for health effects in costbenefit and cost-effectiveness analysis. Health Econ 2001; 10: 587–99PubMedCrossRef
9.
go back to reference Brouwer WBF, van Exel NJ. Discounting in decision making: the consistency argument revisited empirically. Health Policy 2004; 67 (2): 187–94PubMedCrossRef Brouwer WBF, van Exel NJ. Discounting in decision making: the consistency argument revisited empirically. Health Policy 2004; 67 (2): 187–94PubMedCrossRef
10.
go back to reference Brouwer WBF, Rutten FFH, van Hour BA. A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy 2000; 5: 114–8PubMed Brouwer WBF, Rutten FFH, van Hour BA. A fair approach to discounting future effects: taking a societal perspective. J Health Serv Res Policy 2000; 5: 114–8PubMed
11.
go back to reference Morris J, Hammitt JK. Using life expectancy to communicate benefits of health care programs in contingent valuation studies. Med Decis Making 2001; 21 (6: 468–78PubMed Morris J, Hammitt JK. Using life expectancy to communicate benefits of health care programs in contingent valuation studies. Med Decis Making 2001; 21 (6: 468–78PubMed
12.
go back to reference Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997; 6: 117–32PubMedCrossRef Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997; 6: 117–32PubMedCrossRef
13.
go back to reference Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ 2001; 10: 351–6PubMedCrossRef Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ 2001; 10: 351–6PubMedCrossRef
14.
go back to reference Chapman GB, Elstein AS. Valuing the future: temporal discounting of health and money. Med Decis Making 1995; 15 (4): 373–86PubMedCrossRef Chapman GB, Elstein AS. Valuing the future: temporal discounting of health and money. Med Decis Making 1995; 15 (4): 373–86PubMedCrossRef
15.
go back to reference The EuroQol Group. A new facility for the measurement of health-related quality of life. Health Policy 1999; 16 (3): 199–208 The EuroQol Group. A new facility for the measurement of health-related quality of life. Health Policy 1999; 16 (3): 199–208
17.
go back to reference Olsen JA. Time preferences for health gains: an empirical investigation. Health Econ 1993; 2 (3): 257–65PubMedCrossRef Olsen JA. Time preferences for health gains: an empirical investigation. Health Econ 1993; 2 (3): 257–65PubMedCrossRef
18.
go back to reference Centraal Bureau voor de Statistiek 26, 2004 [online]. Available from URL: http://www.ebs.nl [Accessed 6 May 2005] Centraal Bureau voor de Statistiek 26, 2004 [online]. Available from URL: http://​www.​ebs.​nl [Accessed 6 May 2005]
19.
go back to reference Cairns JA, Van der Pol M. Constant and decreasing timing aversion for saving lives. Soc Sci Med 1997; 45 (11): 1653–9PubMedCrossRef Cairns JA, Van der Pol M. Constant and decreasing timing aversion for saving lives. Soc Sci Med 1997; 45 (11): 1653–9PubMedCrossRef
20.
go back to reference Cairns JA, Van der Pol M. Saving future lives: a comparison of three discounting models. Health Econ 1997; 6 (4): 341–50PubMedCrossRef Cairns JA, Van der Pol M. Saving future lives: a comparison of three discounting models. Health Econ 1997; 6 (4): 341–50PubMedCrossRef
21.
go back to reference Chapman GB. Time preferences for the very long time. Acta Psychol (Amst) 2001; 108: 95–116CrossRef Chapman GB. Time preferences for the very long time. Acta Psychol (Amst) 2001; 108: 95–116CrossRef
22.
go back to reference The Economist. Consistently inconsistent, in The Economist Print Edition, 1999 The Economist. Consistently inconsistent, in The Economist Print Edition, 1999
23.
go back to reference Cairns JA, Van der Pol M. Negative and zero time preference for health. Health Econ 1999; 9 (2): 171–5 Cairns JA, Van der Pol M. Negative and zero time preference for health. Health Econ 1999; 9 (2): 171–5
24.
go back to reference Cairns JA, Van der Pol M. The estimation of marginal time preference in a UK-wide sample. Health Technol Assess 2000; 4 (1): 1–83PubMed Cairns JA, Van der Pol M. The estimation of marginal time preference in a UK-wide sample. Health Technol Assess 2000; 4 (1): 1–83PubMed
25.
go back to reference van Nooten F, Brouwer WBF. The influence of subjective expectations about length and quality of life on time trade-off answers. Health Econ 2004; 13: 819–23PubMedCrossRef van Nooten F, Brouwer WBF. The influence of subjective expectations about length and quality of life on time trade-off answers. Health Econ 2004; 13: 819–23PubMedCrossRef
26.
go back to reference Van den Berg B, Brouwer WBF, van Exel NJ, et al. Economic valuation of informal care: the contingent valuation method applied in informal caregiving. Health Econ 2005; 14 (2): 169–83PubMedCrossRef Van den Berg B, Brouwer WBF, van Exel NJ, et al. Economic valuation of informal care: the contingent valuation method applied in informal caregiving. Health Econ 2005; 14 (2): 169–83PubMedCrossRef
27.
go back to reference Kartman B, Stalhammar NO, Johannesson M. Contingent valuation with an open-ended follow-up question: a test of scope effects. Health Econ 1997; 6 (6: 637–9PubMedCrossRef Kartman B, Stalhammar NO, Johannesson M. Contingent valuation with an open-ended follow-up question: a test of scope effects. Health Econ 1997; 6 (6: 637–9PubMedCrossRef
Metadata
Title
Societal discounting of health effects in cost-effectiveness analyses
The influence of life expectancy
Authors
Dr Suzanne Polinder
Willem Jan Meerding
Job van Exel
Werner Brouwer
Publication date
01-08-2005
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2005
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200523080-00005

Other articles of this Issue 8/2005

PharmacoEconomics 8/2005 Go to the issue

Correspondence

The authors’ reply